Long noncoding RNAs (lncRNAs) constitute the largest class of noncoding RNAs and play significant roles in the development of cardiovascular pathologies. In the present study, we aimed to evaluate whether 4 candidate lncRNAs – MIAT, MEG3, MALAT1, and MCM3AP-AS1 – have distinct expression levels in patients with obstructive coronary artery disease (CAD) and reveal the diagnostic and therapeutic potentials of these lncRNAs for CAD. A total of 90 patients who subjected to coronary angiography were enrolled. Relative expression of lncRNAs were assayed using qRT-PCR methodology. As a result, MIAT was downregulated, while MEG3 was upregulated in CAD patients. Receiver operating characteristic curves demonstrated that these lncRNAs have a high potential to provide sensitive and specific diagnosis of CAD. The calculated area under curve levels indicated that MIAT and MEG3 have high diagnostic value for detecting the presence of significant CAD. However, MALAT1 and MCM3AP-AS1 levels were not sufficiently reliable for CAD development in our cases. Here, we demonstrate that MIAT and MEG3 were differentially expressed in our patients and might be promising biomarkers and therapeutic targets for CAD. These results indicate that MIAT and MEG3 could play chief roles in CAD development.
Mol Syndromol

中文翻译：

---

冠状动脉疾病患者中长链非编码 RNA 的差异表达

长链非编码 RNA (lncRNA) 构成最大类的非编码 RNA，在心血管疾病的发展中发挥重要作用。在本研究中，我们旨在评估 4 种候选 lncRNA——MIAT、MEG3、MALAT1 和 MCM3AP-AS1——是否在阻塞性冠状动脉疾病 (CAD) 患者中具有不同的表达水平，并揭示这些 lncRNA 的诊断和治疗潜力加元。共有 90 名接受冠状动脉造影的患者入组。使用 qRT-PCR 方法测定 lncRNA 的相对表达。结果，MIAT被下调，而MEG3在 CAD 患者中上调。受试者工作特征曲线表明，这些 lncRNA 具有很高的潜力来提供对 CAD 的敏感和特异性诊断。计算的曲线水平下面积表明 MIAT 和 MEG3 对于检测是否存在显着 CAD 具有较高的诊断价值。然而，在我们的案例中， MALAT1和MCM3AP-AS1水平对于 CAD 开发不够可靠。在这里，我们证明MIAT和MEG3在我们的患者中存在差异表达，可能是 CAD 的有希望的生物标志物和治疗靶点。这些结果表明MIAT和MEG3可以在 CAD 开发中发挥主要作用。
摩尔综合症